Company intelligence / Profile preview

Akyso Pharmaceuticals

Salisbury, Maryland, United Statesakysomed.com ↗

Ownership: Private
Development stage: Other

Overview

Akyso Pharmaceuticals is developing a proprietary sustained-release, subcutaneous naltrexone implant for opioid use disorder. Preclinical studies have shown safety and efficacy in animal models; IND-enabling toxicology and biocompatibility studies are complete. The first-in-human Phase 1 trial is expected to begin recruitment imminently or has recently started. The product aims to deliver naltrexone over at least six months with tunable release kinetics.

Therapeutic areas: Psychiatry
Modalities: Implantable deviceSmall moleculePolymer-drug conjugate therapy
Industry: Biotech

Partnerships

National Institute on Drug Abuse/National Institutes of Health grant

Beyond the preview

Go deeper on Akyso Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Akyso Pharmaceuticals.

Explore the full profile